Advertisement Cynapsus gets second grant from The Michael J. Fox Foundation for Parkinson's research - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cynapsus gets second grant from The Michael J. Fox Foundation for Parkinson’s research

Cynapsus Therapeutics has been awarded a new grant of US$500,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support clinical studies to develop APL-130277, a sublingual thin film strip reformulation of apomorphine.

This second MJFF grant will be used to fund the Company’s CTH-105 clinical study.

APL-130277 is an easy-to-administer, fast-acting and proprietary reformulation of apomorphine for sublingual delivery. Injectable apomorphine is the only approved drug in the United States, Europe, Japan and other countries for the acute rescue of "off" motor symptoms of Parkinson’s disease.

The APL-130277 thin film strip system technology is specifically designed to provide enhanced convenience and eliminate buccal mucosal irritation, among other attributes.

CTH-105 is a pilot study in patients with Parkinson’s disease who are naïve to the use of apomorphine and who experience at least one daily "off" episode with a total duration of "off" in any 24-hour period of at least 2 hours.

This study is planned to examine the effect of APL-130277 on relieving "off" episodes over a single day with a dose-titration used to determine dose strengths necessary for future clinical development. This study and future trials of APL-130277 will be listed on Fox Trial Finder, an online tool from MJFF matching interested research volunteers with recruiting clinical studies.

"The options for patients living with ‘off’ episodes are limited and unfavorable," says Maurizio Facheris, MD, MSc, Associate Director of Research Programs at MJFF. "Initial results of Cynapsus’ novel formulation (APL-130277) show this therapy may offer not only a more palatable solution for motor fluctuations, but also a longer window of efficacy, thereby postponing dopamine replacement dosing and lessening associated side effects."

"This second grant from The Michael J. Fox Foundation is very important to Cynapsus, as it solidifies the partnership we have forged with the Foundation to focus on improving the daily lives of Parkinson’s patients," said Mr. Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus. "The CTH-105 clinical trial is our first in Parkinson’s patient study of APL-130277 and will assist us with dosing information required for the CTH-300a registration study, which is expected to begin in Q4 2014."

Dr. Albert Agro, the Principal Investigator for the study and the Chief Medical Officer of Cynapsus added: "The continued support of The Michael J. Fox Foundation validates our clinical approach and justifies the need for an improved formulation of apomorphine in the form of APL-130277. With the help of the MJFF, we are excited about moving APL-130277 in to patients this summer in the CTH-105 Phase 2 study."

The MJFF previously awarded Cynapsus an initial grant of $947,925 to complete a comparative study of APL-130277 (i.e. CTH-103) versus subcutaneous injection. The results of the CTH-103 study were announced on January 13, 2014.

Parkinson’s disease is a chronic, degenerative neurological disorder that results from the loss of dopamine-producing nerve cells in the brain. Current treatments for Parkinson’s disease are able to reduce the symptoms of the disease but are not able to treat the underlying neurodegenerative processes.

It is estimated that over one million people in the United States and 4 to 6 million people globally are living with Parkinson’s disease. According to the U.S. National Institute of Neurodegenerative Disease and Stroke, the average age of onset is 60, though some people are diagnosed at age 40 or younger.

As part of the MJFF grant agreement, Cynapsus has made a commitment to support further Parkinson’s research by making up to $1 million in contributions to MJFF based on future potential sales of APL-130277.